Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Melanoma 2Multiple Myeloma 1Lymphoma, B-Cell 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1B-Cell Malignancies 1Advanced Solid Tumors 1Advanced Solid Malignancies 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × urelumab × Clear all
NCT02534506 2020-05-18

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Bristol-Myers Squibb

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated
115 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡